These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 33509107)

  • 1. Substitution of citrate with tissue plasminogen activator (rt-PA) for catheter lock does not improve patency of tunnelled haemodialysis catheters in a randomised trial.
    Richtrova P; Mares J; Kielberger L; Klaboch J; Eiselt J; Reischig T
    BMC Nephrol; 2021 Jan; 22(1):41. PubMed ID: 33509107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and Cost of Weekly Recombinant Tissue Plasminogen Activator Hemodialysis Catheter Locking Solution.
    Hemmelgarn BR; Manns BJ; Soroka SD; Levin A; MacRae J; Tennankore K; Wilson JS; Weaver RG; Ravani P; Quinn RR; Tonelli M; Kiaii M; Mossop P; Scott-Douglas N
    Clin J Am Soc Nephrol; 2018 Mar; 13(3):429-435. PubMed ID: 29335321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator.
    Hemmelgarn BR; Moist LM; Lok CE; Tonelli M; Manns BJ; Holden RM; LeBlanc M; Faris P; Barre P; Zhang J; Scott-Douglas N;
    N Engl J Med; 2011 Jan; 364(4):303-12. PubMed ID: 21268722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoration of flow following haemodialysis catheter thrombus. Analysis of rt-PA infusion in tunnelled dialysis catheters.
    Davies J; Casey J; Li C; Crowe AV; McClelland P
    J Clin Pharm Ther; 2004 Dec; 29(6):517-20. PubMed ID: 15584939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of heparin to citrate as a catheter locking solution for non-tunneled central venous hemodialysis catheters in patients requiring renal replacement therapy for acute renal failure (VERROU-REA study): study protocol for a randomized controlled trial.
    Bruyère R; Soudry-Faure A; Capellier G; Binquet C; Nadji A; Torner S; Blasco G; Yannaraki M; Barbar SD; Quenot JP
    Trials; 2014 Nov; 15():449. PubMed ID: 25409678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of catheter lumen occlusion with rT-PA versus heparin (Pre-CLOT): study protocol of a randomized trial [ISRCTN35253449].
    Hemmelgarn BR; Moist L; Pilkey RM; Lok C; Dorval M; Tam PY; Berall MJ; LeBlanc M; Toffelmire EB; Manns BJ; Scott-Douglas N;
    BMC Nephrol; 2006 Apr; 7():8. PubMed ID: 16608513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefazolin-gentamicin versus taurolidine-citrate for the prevention of infection in tunneled central catheters in hemodialysis patients: A quasi-experimental trial.
    Bueloni TNV; Marchi D; Caetano C; de Souza Cavalcante R; Mendes Amaral ML; Ponce D
    Int J Infect Dis; 2019 Aug; 85():16-21. PubMed ID: 31102823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urokinase-containing locking solution in the prevention of dialysis catheter dysfunction: a double blind randomized controlled trial.
    Bonkain F; Van Hulle F; Janssens P; Catalano C; Allamani M; Stolear JC; Vandervelde D; Libertalis M; Treille S; Couttenye MM; Dhondt A; Van Biesen W; Fils JF; Tielemans C; Wissing KM
    J Vasc Access; 2017 Sep; 18(5):436-442. PubMed ID: 28623638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of taurolidine/urokinase versus taurolidine/heparin as a tunneled catheter lock solution in hemodialysis patients: a prospective, randomized, controlled study.
    Al-Ali F; Hamdy AF; Hamad A; Elsayed M; Zafar Iqbal Z; Elsayed A; Ibrahim R; Tolba H; Buanan H; Fawzy A
    Nephrol Dial Transplant; 2018 Apr; 33(4):619-626. PubMed ID: 29106676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors associated with hemodialysis central venous catheter malfunction; a retrospective analysis of a randomized controlled trial.
    Ward DR; Moist LM; MacRae JM; Scott-Douglas N; Zhang J; Tonelli M; Lok CE; Soroka SD; Hemmelgarn BR
    Can J Kidney Health Dis; 2014; 1():15. PubMed ID: 25960883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of intensive versus standard hemodialysis central venous catheter dysfunction protocol using rt-PA: a quality assurance initiative.
    Wilson JA; Mossop P; Soroka SD; Dipchand C; Drost S; Sheehy N; Tennankore K
    J Vasc Access; 2016; 17(2):143-50. PubMed ID: 26847735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taurolidine-based catheter lock regimen significantly reduces overall costs, infection, and dysfunction rates of tunneled hemodialysis catheters.
    Winnicki W; Herkner H; Lorenz M; Handisurya A; Kikić Ž; Bielesz B; Schairer B; Reiter T; Eskandary F; Sunder-Plassmann G; Sengoelge G
    Kidney Int; 2018 Mar; 93(3):753-760. PubMed ID: 28890326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Citrate versus heparin lock for prevention of hemodialysis catheter-related complications: updated systematic review and meta-analysis of randomized controlled trials.
    Mai H; Zhao Y; Salerno S; Li Y; Feng Y; Ma L; Fu P
    Int Urol Nephrol; 2019 Jun; 51(6):1019-1033. PubMed ID: 31012037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precurved non-tunnelled catheters for haemodialysis are comparable in terms of infections and malfunction as compared to tunnelled catheters: A retrospective cohort study.
    van Oevelen M; Abrahams AC; Weijmer MC; Nagtegaal T; Dekker FW; Rotmans JI; Meijvis SC;
    J Vasc Access; 2019 May; 20(3):307-312. PubMed ID: 30345873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low dose heparin lock (1000 U/mL) maintains tunnelled hemodialysis catheter patency when compared with high dose heparin (5000 U/mL): A randomised controlled trial.
    Chu G; Fogarty GM; Avis LF; Bergin S; McElduff P; Gillies AH; Choi P
    Hemodial Int; 2016 Jul; 20(3):385-91. PubMed ID: 26833752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT).
    Gudiol C; Nicolae S; Royo-Cebrecos C; Aguilar-Guisado M; Montero I; Martín-Gandul C; Perayre M; Berbel D; Encuentra M; Arnan M; Cisneros-Herreros JM; Carratalà J
    Trials; 2018 May; 19(1):264. PubMed ID: 29720244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trisodium citrate 46.7% selectively and safely reduces staphylococcal catheter-related bacteraemia.
    Winnett G; Nolan J; Miller M; Ashman N
    Nephrol Dial Transplant; 2008 Nov; 23(11):3592-8. PubMed ID: 18503094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of rt-PA infusion in tunnelled dialysis catheters.
    Davies J; Casey J; Li C; Crowe AV; McClelland P
    EDTNA ERCA J; 2005; 31(2):75-8. PubMed ID: 16180551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel antimicrobial and antithrombotic lock solution for hemodialysis catheters: a multi-center, controlled, randomized trial.
    Maki DG; Ash SR; Winger RK; Lavin P;
    Crit Care Med; 2011 Apr; 39(4):613-20. PubMed ID: 21200319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of hemodialysis catheter-associated fibrin sheaths by rt-PA infusion: critical analysis of 124 procedures.
    Savader SJ; Ehrman KO; Porter DJ; Haikal LC; Oteham AC
    J Vasc Interv Radiol; 2001 Jun; 12(6):711-5. PubMed ID: 11389222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.